Flamel Technologies of France has signed a letter of intent to acquire SmithKline Beecham's pharmaceutical production facility in Bordeaux, France. Flamel said the 50,000-square foot Bordeaux facility will give it future manufacturing capacity for products now in late-stage development. Under the terms of the deal, Flamel would acquire the plant for a nominal fee and enter into a production agreement with SB to continue to produce cimetidine at the facility.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze